Content about Delaware

August 3, 2012

Harris Teeter plans to expand its presence in existing markets, the company said in its third-quarter earnings release.

MATTHEWS, N.C. — Harris Teeter plans to expand its presence in existing markets, the company said in its third-quarter earnings release.

July 27, 2012

A survey released by Chase Slate with Blueprint revealed that more back-to-school shoppers are carefully managing their spending and borrowing by creating a budget and sticking to it.

WILMINGTON, Del. — A survey released by Chase Slate with Blueprint revealed that more back-to-school shoppers are carefully managing their spending and borrowing by creating a budget and sticking to it.

Thirty-eight percent reported that they have a set budget for school-related expenses; in 2011, only 26% of people had created a budget for their back-to-school shopping. In addition, 32% said they anticipate their spending on back-to-school shopping this year to reflect prerecession figures.

July 24, 2012

A district court ruled in favor of Pfizer and Northwestern University in a patent infringement case relating to Lyrica (pregabalin).

NEW YORK — A district court ruled in favor of Pfizer and Northwestern University in a patent infringement case relating to Lyrica (pregabalin).

June 19, 2012

The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker's abbreviated new drug application for an overactive bladder treatment.

PARSIPPANY, N.J. — The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker's abbreviated new drug application for an overactive bladder treatment.

The appeals court affirmed a U.S. District Court for the District of Delaware's decision — made March 31 — that asserted that patents related to Allergan's Sanctura XR (trospium chloride extended-release capsules) are invalid. Watson's ANDA for a generic version of Sanctura XR is pending with the Food and Drug Administration.

April 19, 2012

Generic drug maker Watson is challenging the patent protection on a drug used to treat Type 2 diabetes.

PARSIPPANY, N.J. — Generic drug maker Watson is challenging the patent protection on a drug used to treat Type 2 diabetes.

Watson said Thursday that it had filed with the Food and Drug Administration for approval of a generic version of Depomed's Glumetza (metformin hydrochloride extended-release tablets) in the 1,000-mg strength.

April 12, 2012

AstraZeneca has launched a new drug for treating high blood pressure, the company said Thursday.

WILMINGTON, Del. — AstraZeneca has launched a new drug for treating high blood pressure, the company said Thursday.

The Anglo-Swedish drug maker announced the launch of Dutoprol (metoprolol succinate extended-release and hydrochlorothiazide) tablets, calling it the first and only pill to combine the active ingredient of its Toprol-XL ER (metoprolol succinate) and hydrochlorothiazide.

April 4, 2012

A court has ruled that patents covering a drug used for overactive bladder are invalid, a company looking to launch a generic version of the drug said.

PARSIPPANY, N.J. — A court has ruled that patents covering a drug designed to treat an overactive bladder are invalid, a company looking to launch a generic version of the drug said.

Watson Pharmaceuticals said the U.S. District Court for the District of Delaware ruled that five patents covering Allergan's Sanctura XR (trospium chloride) extended-release capsules were invalid. Watson's application with the Food and Drug Administration for a generic version are pending, the company said.

February 16, 2012

Marley Coffee has inked a distribution agreement that will expands its line's availability on the East Coast, as well as in Hawaii.

LOS ANGELES — Marley Coffee has inked a distribution agreement that will expands its line's availability on the East Coast, as well as in Hawaii.

February 14, 2012

Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.

PITTSBURGH — Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.

Sunovion Pharmaceuticals sued Mylan and several subsidiaries in the U.S. District Court for the District of Delaware when the latter sought to market a generic version of Sunovion's Xopenex (levalbuterol hydrochloride) inhalation solution, a drug for asthma and chronic obstructive pulmonary disease. The jury's verdict includes an $18 million award.

December 13, 2011

Unilever’s Dove Hair has announced the real woman star of its new “Make Friends with Your Hair” television ad campaign.

ENGLEWOOD CLIFFS, N.J. — Unilever’s Dove Hair has announced the real woman star of its new “Make Friends with Your Hair” television ad campaign.

The winner is Brittany Delaware, 23, of Teleford, Pa. Delaware joined women across the country and created a video of her own hair struggles for the campaign. America voted and Delaware was selected to receive a VIP trip to New York, a hair transformation from Dove celebrity stylist Mark Townsend and a starring role in the new Dove Hair TV ad.

 

November 15, 2011

The generic drug lobby is stepping up its efforts to persuade the congressional super committee to avoid adopting rules that would ban some patent settlements between branded and generic drug makers.

WASHINGTON — The generic drug lobby is stepping up its efforts to persuade the congressional super committee to avoid adopting rules that would ban some patent settlements between branded and generic drug makers.

October 19, 2011

The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO’s drugs by the end of the decade.

SUPPLIER NEWS — The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO’s drugs by the end of the decade. The drug makers announced the settlement in the U.S. District Court for the District of Delaware, whereby Teva can launch a generic version of the injectable anticoagulant drug Angiomax (bivalirudin) in June 2019.


October 4, 2011

The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO's drugs by the end of the decade.

PARSIPPANY, N.J. — The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO's drugs by the end of the decade.

The drug makers announced the settlement in the U.S. District Court for the District of Delaware, whereby Teva can launch a generic version of the injectable anticoagulant drug Angiomax (bivalirudin) in June 2019.

September 30, 2011

A fifth dietary supplement trade association may be in the early formulation stages, specifically designed to address the Food and Drug Administration's recent issues of New Dietary Ingredient guidance, according to a Nutrition Business Journal report published Wednesday.

BOULDER, Colo. — A fifth dietary supplement trade association may be in the early formulation stages, specifically designed to address the Food and Drug Administration's recent issues of New Dietary Ingredient guidance, according to a Nutrition Business Journal report published Wednesday.

September 13, 2011

Impax Labs has hit a roadblock in its attempt to market a generic version of a symptomatic benign prostatic hyperplasia drug.

HAYWARD, Calif. — Impax Labs has hit a roadblock in its attempt to market a generic version of a symptomatic benign prostatic hyperplasia drug.

September 1, 2011

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

NEW YORK — Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

August 30, 2011

Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.

NEW YORK — Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.

August 22, 2011

A new drug made by AstraZeneca is available in pharmacies following its regulatory approval in July, the company said Monday.

WILMINGTON, Del. — A new drug made by AstraZeneca is available in pharmacies following its regulatory approval in July, the company said Monday.

AstraZeneca announced the availability of the anti-platelet drug Brilinta (ticagrelor) for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome.

The Food and Drug Administration approved Brilinta on July 20. AstraZeneca said the drug has been shown to reduce the rates of cardiovascular death, heart attacks and stroke, compared with other drugs on the market.

July 21, 2011

The Food and Drug Administration has approved a drug made by AstraZeneca to reduce the rate of heart attacks in patients with acute coronary syndrome, the Anglo-Swedish drug maker said.

WILMINGTON, Del. — The Food and Drug Administration has approved a drug made by AstraZeneca to reduce the rate of heart attacks in patients with acute coronary syndrome, the Anglo-Swedish drug maker said.

AstraZeneca announced the approval of Brilinta (ticagrelor), a blood-thinning drug, on Wednesday. The drug maker is touting the drug as an alternative to Plavix (clopidogrel), made by Sanofi and Bristol-Myers Squibb.

July 20, 2011

A Food and Drug Administration committee of experts has advised against approving a drug for Type 2 diabetes made by AstraZeneca and Bristol-Myers Squibb, the companies said Tuesday.

WILMINGTON, Del. — A Food and Drug Administration committee of experts has advised against approving a drug for Type 2 diabetes made by AstraZeneca and Bristol-Myers Squibb, the companies said Tuesday.

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 against recommending approval for dapagliflozin, saying that data from a two-year clinical trial program that included about 6,000 people did not support the drug’s approval for use in patients along with changes to diet and exercise.

July 6, 2011

Grocer A&P has announced the launch of a new Preferred Pet Club program in collaboration with the American Society for the Prevention of Cruelty to Animals, offering exclusive discounts to pet owners across New York, New Jersey, Pennsylvania, Delaware and Connecticut.

MONTVALE, N.J. — Grocer A&P has announced the launch of a new Preferred Pet Club program in collaboration with the American Society for the Prevention of Cruelty to Animals, offering exclusive discounts to pet owners across New York, New Jersey, Pennsylvania, Delaware and Connecticut.

June 8, 2011

Dr. Fresh, a maker of personal care products, perhaps best known for its FireFly flashing toothbrush for children, has announced that a Wilmington dentist has won recognition for making pediatric dental services available to uninsured, needy local families.

WILMINGTON, Del. — Dr. Fresh, a maker of personal care products, perhaps best known for its FireFly flashing toothbrush for children, has announced that a Wilmington dentist has won recognition for making pediatric dental services available to uninsured, needy local families.

Brendan Fay was recognized in a national contest sponsored by FireFly toothbrush, which is part of the company's ongoing Crusade Against Cavities initiative.

May 26, 2011

Giant Food is donating nearly $2 million to schools in Maryland, Virginia, Delaware and the District of Columbia as part of its 2010-2011 A+ School Rewards program, the Royal Ahold banner said Wednesday.

LANDOVER, Md. — Giant Food is donating nearly $2 million to schools in Maryland, Virginia, Delaware and the District of Columbia as part of its 2010-2011 A+ School Rewards program, the Royal Ahold banner said Wednesday.

The program, which has operated for 22 years, allows customers to support school programs every time they use their Giant card at a Giant Food store.

May 23, 2011

The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


SUPPLIER NEWS — The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


May 13, 2011

Walgreens is 10 stores into transforming the popular Happy Harry’s Delaware pharmacy brand into Walgreens stores both inside and out, the News Journal, a Delaware daily, reported earlier this week.

HOCKESSIN, Del. — Walgreens is 10 stores into transforming the popular Happy Harry’s Delaware pharmacy brand into Walgreens stores both inside and out, the News Journal, a Delaware daily, reported earlier this week.

By the end of the year, Happy Harry’s will be no more. Walgreens acquired Happy Harry’s in 2006, but decided to keep the venerable brand name at the time.